![]() |
![]() |
![]() |
Management and BoardManagement
Board
|
Dan Roach
He was a co-founder of Peptide Therapeutics (now Acambis) in 1993 where he was Commercial Director, CeNeS in 1996 where he was CEO from 1997-2002, Amura in 1997 and Avlar in 1998. He is currently an investment director of Avlar, the ATM group of companies, and on the Board of several Avlar investment companies.
He is Entrepreneur in Residence at the Centre for Entrepreneurial Learning and to the Greater Cambridge Partnership (GCP) Operating Board. Dan has been a board trustee of the Babraham Institute and Chairman of ERBI. He was one of the first students to read biochemistry at the University of Swansea and has a PhD in enzymology from Bath University, funded by Porton Down. |



Dan joined PA Consulting Group in 1985, becoming Business Development Manager for the Biotechnology Group. In 1993, he joined Advanced Technology Management Limited (ATM), a company established by Alan Goodman which has been involved in forming and seeding nine companies, seven of which subsequently listed on Stock Exchanges - Acambis, Chiroscience, CeNeS, Core, Lidco, Oxford Biomedica and Salix.